Navigation Links
TechniScan Launches 3-D Breast Ultrasound Clinical Study in Freiburg University
Date:3/2/2010

SALT LAKE CITY, March 2 /PRNewswire-FirstCall/ -- TechniScan, Inc. (OTC Bulletin Board: TSNI) ("TechniScan" or the "Company"), a medical device company engaged in the development and commercialization of an automated 3-D breast ultrasound imaging system, today announced that in collaboration with University Medical Center Freiburg in Germany, it has launched a clinical study to assess clinical utility of TechniScan's Warm Bath Ultrasound.

TechniScan's Warm Bath Ultrasound (WBU™) system is designed for state-of-the-art ultrasound technology, used in a warm water tank, to capture 3-D images of the breast as a woman lies prone on a table.

The University Medical Center Freiburg was founded in 1457 and is one of the most prestigious and reputable hospitals in Europe due to its extensive clinical capabilities and advances in medical research. The Breast Examination Center of the Radiology Department, University Medical Center Freiburg is a regional center for women's health and it is the ideal place for the study.  

Clinicians will scan a total of at least 150 women within three defined groups: Those with normal mammography findings, those with known benign lesions, and those with known malignancies. The study includes direct comparison of TechniScan's WBU™ images against mammogram, MRI and hand held ultrasound to directly evaluate the ability of WBU™ in providing comparative diagnostic findings.  

Italian medical imaging company Esaote cooperated with TechniScan in the development of the WBU™ system and will support TechniScan's efforts in Europe and in Italy. "The Warm Bath Ultrasound system has been developed with groundbreaking science and technology," said Dr. Luigi Satragno, R&D and strategic marketing general manager of Esaote.  "We look forward to seeing the clinical studies results and to a long and productive partnership with TechniScan."

Radiologists involved in the Freiburg study will utilize TechniScan's imaging network which provides them with the ability to archive, store, and retrieve anonymous WBU™ images and relevant medical records and will discuss and compare their results with other researchers.  

"Our vision is to begin to create a database of thousands of anonymous breast images and related data," said Dave Robinson, chief executive officer at TechniScan, Inc. "This scientific database will consist of anonymous mammograms, breast MRIs and WBU™ images, along with related pathology and other information, to provide researchers around the world an unprecedented opportunity to study breast cancer. The concept is simple, yet revolutionary within the medical system and represents a key competitive advantage of the TechniScan system."

About Esaote

Esaote is one of the fastest growing medical imaging companies in the world specializing in high performance ultrasound systems and is a key investor in TechniScan, Inc.  Esaote's premium hand held ultrasound system, the MyLab 70 XVG, is integrated into TechniScan's Warm Bath Ultrasound system to provide both automated reflection imaging and to aid in hand-guided breast biopsy. As the key OEM supplier for the WBU™ system, Esaote provides TechniScan with support for engineering, regulatory and manufacturing initiatives.

About TechniScan, Inc.

Based in Salt Lake City, Utah, TechniScan, Inc. is a medical device company engaged in the development and commercialization of a non-invasive imaging tool designed to provide physicians with automated ultrasound images of the human breast. The system uses a process called Warm Bath Ultrasound (WBU™) to provide physicians with automated, 3-D, ultrasound images of the physical structures within the breast. TechniScan's WBU™ imaging device is limited by U.S. law to investigational use unless, and until, cleared by the FDA. For more information, please visit www.techniscanmedical.com.

Forward-Looking Statements

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as "anticipate," "believe," "expect," "future," "may," "will," "would," "should," "plan," "projected," "potential," "intend," and similar expressions. Such forward-looking statements, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of TechniScan, Inc. (the "Company") to be materially different from those expressed or implied by such forward-looking statements. The Company's future operating results are dependent upon many factors, including risk factors discussed in the Company's periodic filings with the Securities and Exchange Commission, which are available for review at www.sec.gov, including the Company's Current Report on Form 8-K filed on October 16th, 2009. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE TechniScan, Inc.

Back to top

RELATED LINKS
http://www.techniscanmedical.com

'/>"/>

SOURCE TechniScan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
2. TechniScan Cofounder to Speak at SPIE Medical Imaging Conference About Ground-Breaking Science Behind the Companys Ultrasound Technology
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
6. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
9. Premier Micronutrient Launches Supplement for Hearing Health
10. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
11. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations ... Latin America . ... ... ... ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... ... 26, 2016 , ... PawPaws brand pet supplements owned by Whole ... enhance the health of felines. The formula is all-natural and is made from Chinese ... PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
Breaking Medicine News(10 mins):